Nebacumab

CHEMBL2109181 Phase 4 Đã phê duyệt Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

An anti-lipid A antibody that was investigated to treat gram-negative sepsis and endotoxin shock by neutralizing bacterial endotoxin. It did not demonstrate clinical benefit in trials and was never approved.

Lĩnh vực điều trị

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

An anti-lipid A antibody that was investigated to treat gram-negative sepsis and endotoxin shock by neutralizing bacterial endotoxin. It did not demonstrate clinical benefit in trials and was never approved.

Yes, Nebacumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2109181. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.